DadFinStart your free week
DadFin › Stocks › Healthcare › ACB

Aurora Cannabis Inc. (ACB) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Canada

$4.49 ▲ +1.35% today

51.6
Dad Score, out of 100
middling

Aurora Cannabis Inc. (ACB) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Canada. On DadFin's weekly run it scores 51.6 out of 100 on the Dad Score, a middling reading that places the business ahead of 52% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #399 of 974. Its strongest axes are price action and risk; its weakest are quality and growth.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Average
Quality
Weak
Growth
Below average
Price action
Above average
Risk
Above average
Conviction
Weak
Liquidity
Below average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-35.6×
Dividend yield0.00%
Return on capital-24.7%
Operating margin-12.9%
Revenue growth (YoY)+11.0%
FCF yield-19.6%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change-32.5%
Market cap$248M
Next earningsNov 4, 2026

What subscribers see on ACB

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.